|
| 36082969 | Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial. | J Clin Oncol | 2023 |
| 37591609 | Low-grade serous ovarian cancer: expert consensus report on the state of the science. | Int J Gynecol Cancer | 2023 |
| 37651655 | Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study. | J Clin Oncol | 2023 |
| 38055253 | Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer. | N Engl J Med | 2023 |
| 37581616 | Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer. | Clin Cancer Res | 2023 |
| 37072323 | Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study. | Int J Gynecol Cancer | 2023 |
| 37363992 | Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study. | Clin Cancer Res | 2023 |
| 36446254 | Targeting NaPi2b in ovarian cancer. | Cancer Treat Rev | 2023 |
| 36878571 | New therapies for clear cell ovarian carcinoma. | Int J Gynecol Cancer | 2023 |
| 36482193 | Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10. | Br J Cancer | 2023 |
| 36928279 | Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma: The OCTOPUS Multicenter, Phase 2, Randomized Clinical Trial. | JAMA Oncol | 2023 |
| 34727316 | Utilization of Poly(ADP-Ribose) Polymerase Inhibitors in Ovarian Cancer: A Retrospective Cohort Study of US Healthcare Claims Data. | Adv Ther | 2022 |
| 35690073 | Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial. | Lancet Oncol | 2022 |
| 35984704 | A Phase I Trial of CT900, a Novel α-Folate Receptor-Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer. | Clin Cancer Res | 2022 |
| 34952707 | Real-world outcomes in patients with advanced endometrial cancer: A retrospective cohort study of US electronic health records. | Gynecol Oncol | 2022 |
| 35123694 | Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. | Lancet | 2022 |
| 35007996 | The impact of COVID-19 on oncology professionals-one year on: lessons learned from the ESMO Resilience Task Force survey series. | ESMO Open | 2022 |
| 33382149 | PARP inhibitors in ovarian cancer: An overview of the practice-changing trials. | Genes Chromosomes Cancer | 2021 |
| 33601295 | The impact of COVID-19 on oncology professionals: results of the ESMO Resilience Task Force survey collaboration. | ESMO Open | 2021 |
| 33668809 | Under-Treatment of Older Patients with Newly Diagnosed Epithelial Ovarian Cancer Remains an Issue. | Cancers (Basel) | 2021 |
| 33667670 | Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. | Ann Oncol | 2021 |
| 33862001 | Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial. | Lancet Oncol | 2021 |
| 33801991 | Exploring Older Women's Attitudes to and Experience of Treatment for Advanced Ovarian Cancer: A Qualitative Phenomenological Study. | Cancers (Basel) | 2021 |
| 33608144 | Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903). | Gynecol Oncol | 2021 |
| 33722412 | Beyond Teenage and Young Adult Cancer Care: Care Experiences of Patients Aged 25-39 Years Old in the UK National Health Service. | Clin Oncol (R Coll Radiol) | 2021 |
| 34950880 | Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study. | Nat Cancer | 2021 |
| 35121899 | Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. | Nat Cancer | 2021 |
| 35121900 | Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. | Nat Cancer | 2021 |
| 34412908 | A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial. | Gynecol Oncol | 2021 |
| 34640467 | Describing Unmet Supportive Care Needs among Young Adults with Cancer (25-39 Years) and the Relationship with Health-Related Quality of Life, Psychological Distress, and Illness Cognitions. | J Clin Med | 2021 |
| 34549539 | Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety. | Cancer Med | 2021 |
| 34580668 | Functional antibody and T-cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. | Res Sq | 2021 |
| 34518240 | ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI). | Int J Gynecol Cancer | 2021 |
| 34461484 | Impact of COVID-19 on cancer service delivery: a follow-up international survey of oncology clinicians. | ESMO Open | 2021 |
| 34427115 | Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer. | Future Oncol | 2021 |
| 34625284 | Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903). | Gynecol Oncol | 2021 |
| 34715071 | Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. | Lancet Oncol | 2021 |
| 33942418 | 'This is not part of my life plan': A qualitative study on the psychosocial experiences and practical challenges in young adults with cancer age 25 to 39Â years at diagnosis. | Eur J Cancer Care (Engl) | 2021 |
| 34353615 | Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial. | Gynecol Oncol | 2021 |
| 34103386 | Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3. | Int J Gynecol Cancer | 2021 |
| 34217129 | The concerns of oncology professionals during the COVID-19 pandemic: results from the ESMO Resilience Task Force survey II. | ESMO Open | 2021 |
| 34090547 | ESMO pays tribute to Professor José Baselga. | Ann Oncol | 2021 |
| 34144778 | Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey. | ESMO Open | 2021 |
| 34143970 | Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study. | Lancet Oncol | 2021 |
| 34359755 | Quantitative Assessment and Prognostic Associations of the Immune Landscape in Ovarian Clear Cell Carcinoma. | Cancers (Basel) | 2021 |
| 34312021 | Immunotherapy and Systemic Therapy in Metastatic/Recurrent Endometrial and Cervical Cancers. | Clin Oncol (R Coll Radiol) | 2021 |
| 34051628 | Recent advancements of antiangiogenic combination therapies in ovarian cancer. | Cancer Treat Rev | 2021 |
| 34332292 | PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations. | Cancer Treat Rev | 2021 |
| 33398064 | Biomarkers for site-specific response to neoadjuvant chemotherapy in epithelial ovarian cancer: relating MRI changes to tumour cell load and necrosis. | Br J Cancer | 2021 |
| 31577852 | Longitudinal analysis of a secondary BRCA2 mutation using digital droplet PCR. | J Pathol Clin Res | 2020 |